445 related articles for article (PubMed ID: 33071109)
1. PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy.
Murakami Y; Matsumoto K; Shimizu Y; Ikeda M; Amano N; Shimura S; Ishii D; Sato Y; Iwamura M
Urol Oncol; 2021 Mar; 39(3):195.e15-195.e23. PubMed ID: 33071109
[TBL] [Abstract][Full Text] [Related]
2. Relationship between survival outcomes and microsatellite instability, tumor infiltrating lymphocytes and programmed cell death ligand-1 expression in patients with bladder cancer and radical cystectomy.
Tural D; Akar E; Baytekin HF; Canoglu D; Yilmaz M; Tugcu V
J BUON; 2021; 26(5):2117-2125. PubMed ID: 34761625
[TBL] [Abstract][Full Text] [Related]
3. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
Zhong Q; Shou J; Ying J; Ling Y; Yu Y; Shen Z; Zhang Y; Li N; Shi Y; Zhou A
Future Oncol; 2021 Aug; 17(22):2893-2905. PubMed ID: 34189951
[TBL] [Abstract][Full Text] [Related]
4. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T
Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363
[TBL] [Abstract][Full Text] [Related]
5. Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder.
Owyong M; Lotan Y; Kapur P; Panwar V; McKenzie T; Lee TK; Zi X; Martin JW; Mosbah A; Abol-Enein H; Ghoneim M; Youssef RF
Urol Oncol; 2019 Jul; 37(7):478-484. PubMed ID: 30910351
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of programmed cell death ligand-1 expression in patients with bladder urothelial carcinoma undergoing radical cystectomy: A meta-analysis.
Zhang J; Song L; Zhu H; Liu Q; Wang D
Front Immunol; 2022; 13():986911. PubMed ID: 36248912
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of tumor PD-L1 expression combined with CD8
Wang Q; Lou W; Di W; Wu X
Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
[TBL] [Abstract][Full Text] [Related]
8. The Significance of Squamous Histology on Clinical Outcomes and PD-L1 Expression in Bladder Cancer.
Gordetsky JB; Montgomery KW; Giannico GA; Rais-Bahrami S; Thapa P; Boorjian S; Frank I; Cheville J
Int J Surg Pathol; 2022 Feb; 30(1):6-14. PubMed ID: 34180731
[No Abstract] [Full Text] [Related]
9. Prognostic value of PD-L1 expression in combination with CD8
Yang H; Shi J; Lin D; Li X; Zhao C; Wang Q; Zhang L; Jiang T; Zhao S; Liu X; Jia Y; Zhang Y; Cai W; Zhou C
Cancer Med; 2018 Jan; 7(1):32-45. PubMed ID: 29168339
[TBL] [Abstract][Full Text] [Related]
10. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
Del C Monroig-Bosque P; Driver B; Morales-Rosado JA; Deavers M; Tacha D; Bernicker E; Cagle PT; Miller RA
Arch Pathol Lab Med; 2018 Nov; 142(11):1388-1393. PubMed ID: 29431467
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D
Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013
[TBL] [Abstract][Full Text] [Related]
13. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
Front Immunol; 2021; 12():705378. PubMed ID: 34526987
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
15. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer.
Morihiro T; Kuroda S; Kanaya N; Kakiuchi Y; Kubota T; Aoyama K; Tanaka T; Kikuchi S; Nagasaka T; Nishizaki M; Kagawa S; Tazawa H; Fujiwara T
Sci Rep; 2019 Mar; 9(1):4633. PubMed ID: 30874607
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer.
Mahmoud AM; Frank I; Orme JJ; Lavoie RR; Thapa P; Costello BA; Cheville JC; Gupta S; Dong H; Lucien F
BMC Urol; 2022 Jun; 22(1):90. PubMed ID: 35751046
[TBL] [Abstract][Full Text] [Related]
18. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
19. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z
J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710
[TBL] [Abstract][Full Text] [Related]
20. Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density.
Nukui A; Kamai T; Arai K; Kijima T; Kobayashi M; Narimatsu T; Kambara T; Yuki H; Betsunoh H; Abe H; Fukabori Y; Yashi M; Yoshida KI
Cancer Immunol Immunother; 2020 May; 69(5):689-702. PubMed ID: 32030476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
